Apple won a U.S. trade-court ruling that dismisses Masimo’s bid to reinstate an import ban on the Apple Watch after the ITC found that Apple’s redesigned watch does not infringe Masimo’s blood-oxygen patents, stabilizing Apple’s position in the U.S. market.

The decision does not end Masimo’s litigation, as parallel suits and possible appeals remain active, meaning the dispute will continue across multiple courts and forums.

Masimo, a Danaher subsidiary, has a history of legal action over pulse-oximetry tech and may appeal the ITC ruling to the U.S. Court of Appeals for the Federal Circuit.

For investors, the case adds a note of overvaluation despite strong growth potential, suggesting limited near-term upside and encouraging deeper analysis.

Market context shows Apple stock trading around the mid-$270s with after-hours moves, and the company is viewed as high-quality by market metrics.

Insider activity over the past three months shows about $24.2 million in Apple shares sold and no purchases, signaling potential insider caution about current valuation.

The article reporting on the ruling is dated April 17, 2026, with attribution to Dani Kass and Law360.

Market impact includes price reductions for Apple Watch Series 11 and Watch SE 3 at major retailers, reflecting competitive and pricing dynamics.

GF Score analysis shows strong profitability and growth signals, but only moderate financial strength and valuation to consider.

Disclosures note potential personal holdings and that the analysis underwent editorial review.

GF Value suggests Apple was about 12% overvalued at roughly $241.23, with a GF Score of 98/100 driven by profitability and growth, indicating cautious upside.

GuruFocus provides context on Apple’s market position and size, including a broad ecosystem and Masimo’s link as a Danaher subsidiary in the litigation.